MD

AI MemoPost-earnings T+1

Pediatrix Medical Group

As of 2026-10-30/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-30 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q3 earnings beat and higher EBITDA guidance floor • 2026-10-29

Base target: $29 / p=50% prob

Biggest risk

Q3 adjusted EBITDA fell from $87.3 million to $85.5 million despite revenue growth; higher clinical salaries and other existing-unit expenses offset gains. Hospital-based volume and NICU days remained negative, and the improved adjusted EPS also reflects a lower share count. Broader post-print estimate revisions are not yet verified. SEC earnings exhibit

Invalidation

Break below $23 or thesis failure.

What would change my mind?

Q3 adjusted EPS exceeded the $0.65 consensus reported by Investing.com, the 2026 adjusted EBITDA guidance floor rose by $10 million, and same-unit volume turned modestly positive. Truist reportedly raised its target to $31 from $28 on October 30 while retaining Hold; this is one revision, not broad analyst confirmation. SEC earnings exhibit consensus report Truist revision report

Research note

Recommendation

—

Confidence

medium

As of

2026-10-30

Base target

$29

p=50%

Bull target

$34

p=25%

Bear target

$23

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Patient-volume improvement versus clinical cost pressure
Q3 adjusted EPS exceeded the $0.65 consensus reported by Investing.com, the 2026 adjusted EBITDA guidance floor rose by $10 million, and same-unit volume turned modestly positive.
Truist reportedly raised its target to $31 from $28 on October 30 while retaining Hold; this is one revision, not broad analyst confirmation.

BearKey bullets

Clinical salary inflation, payer-mix changes, Medicaid policy and revenue-cycle transition costs could pressure margins or cash conversion.
SEC earnings exhibit
Hospital-based patient services fell 0.3% and NICU days fell 0.1% year over year in Q3 despite overall same-unit volume improvement.

WatchKey bullets

Q3 earnings beat and higher EBITDA guidance floor

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $29 (p=50%)

Target spread vs base: +17% / -21%

Scenario probabilities

Bull Target: $34 (p=25%)Base Target: $29 (p=50%)Bear Target: $23 (p=25%)

Commentary

The stock closed October 29 at the supplied $29.18 anchor, up $0.27 or 0.93% on the release day; the modest close-to-close gain does not establish a lasting earnings rerating. Price history Truist's reported October 30 target increase is an initial revision, but broader post-print analyst and estimate changes remain unavailable. Consensus providers differ on the EPS benchmark, so the surprise magnitude is not fully settled. Zero-valued sentiment fields mean unavailable, not neutral; no sufficiently covered social, options, short-interest or employee signal was supplied. The positive deterministic prior supports monitoring for follow-through, not upgrading this to a high-conviction buy.

As of 2026-10-30 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Patient-volume improvement versus clinical cost pressure

Scenarios

Bull Target (Scenario probability)

$34 / p=25% prob

Base Target (Scenario probability)

$29 / p=50% prob

Bear Target (Scenario probability)

$23 / p=25% prob

Analysis 2026-10-30 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-29
Q3 earnings beat and higher EBITDA guidance floor
Pediatrix reported Q3 adjusted EPS of $0.72 and revenue of $501.4 million. Investing.com reported consensus of $0.65 and about $498.2 million, respectively. The company narrowed 2026 adjusted EBITDA guidance to $290 million–$300 million from the prior $280 million–$300 million range. A beat and higher guidance floor are positive, but Q3 adjusted EBITDA declined year over year to $85.5 million. [#8-K-2026-10-29] [#SEC-8K-2026-10-29] SEC earnings exhibit consensus report
Prob 100.00% • Move 1.00% • Priced-in 90.00%
EVENT2027-02-28
Fourth-quarter EBITDA needed to meet 2026 outlook
Nine-month adjusted EBITDA was $220.1 million, so the company's $290 million–$300 million full-year outlook implies roughly $69.9 million–$79.9 million in Q4; this is an arithmetic bridge, not separate guidance. The date is an indicative year-end-results monitoring horizon, not an announced release date. [#8-K-2026-10-29] SEC earnings exhibit
Prob 65.00% • Move 5.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Patient-volume improvement versus clinical cost pressure
2027-03-31
Q3 same-unit patient-volume revenue rose 0.3% after falling 2.1% in Q2, while office-based services rose 2.9%. Hospital-based services and NICU days remained slightly negative, and higher existing-unit expenses more than offset revenue growth in Q3 adjusted EBITDA. Sustained volume gains without further margin erosion remain unproven. The date is an indicative monitoring horizon. [#SEC-8K-2026-08-04] [#SEC-8K-2026-10-29] SEC Q3 earnings exhibit
Prob 50% • Move 7% • Priced-in 35%

Risks

Clinical salary inflation, payer-mix changes, Medicaid policy and revenue-cycle transition costs could pressure margins or cash conversion. SEC earnings exhibit
Hospital-based patient services fell 0.3% and NICU days fell 0.1% year over year in Q3 despite overall same-unit volume improvement. SEC earnings exhibit
Meeting full-year EBITDA guidance still requires approximately $69.9 million–$79.9 million in Q4 adjusted EBITDA, based on reported nine-month results. SEC earnings exhibit
Q3 adjusted EBITDA declined year over year as existing-unit expenses rose faster than revenue. SEC earnings exhibit

Peers

Symbol	Summary
ABT	Much larger, device-focused company; not a direct operating or valuation peer. The supplied peer set lacks two close physician-services comparables.
ADUS	Similar-sized healthcare-services issuer, but home care is only an adjacent comparison to Pediatrix's neonatal, maternal-fetal and pediatric physician services.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-30

Loading AI feed…

Symbol

Summary

ABT

Much larger, device-focused company; not a direct operating or valuation peer. The supplied peer set lacks two close physician-services comparables.

ADUS

Similar-sized healthcare-services issuer, but home care is only an adjacent comparison to Pediatrix's neonatal, maternal-fetal and pediatric physician services.